Business Wire

FXCM-GROUP

18.7.2022 10:02:07 CEST | Business Wire | Press release

Share
FXCM Appoints New Chief Marketing Officer

FXCM Group, LLC (‘FXCM Group’ or ‘FXCM’), a leading international provider of online foreign exchange and CFD trading services has today announced the appointment of Paul Gyles as Chief Marketing Officer.

Gyles, a senior, strategic and transformational leader based in London, brings over 15 years of experience in director level marketing positions to FXCM. He previously held marketing director roles at online trading provider, IG as well as Sony and, most recently, M&G.

Paul will be responsible for driving the branding and marketing strategy for FXCM, ensuring the leading provider of online FX and CFD trading continues to be client first, trader driven.

FXCM, recently named Broker of the Year at the Ultimate Fintech Awards, has continually expanded its services throughout 2022, underlining its commitment to a “Client First, Trader Driven” approach. In addition to expanding its CFD offering with the doubling of its French, German and UK share offerings, the firm also launched Australian single share CFD trading with zero data fees and commissions* to enhance the service provided to clients.

Brendan Callan, CEO of FXCM, said: “Paul has broad marketing and management experience and a proven track record in high paced financial services and technology environments, so we’re delighted to have him join the FXCM team. It’s an exciting time for FXCM and we’re confident Paul’s wealth of experience and expertise will prove invaluable in ensuring FXCM remains the premier retail broker of choice.”

Paul Gyles, CMO of FXCM, said: “I’m excited to join the FXCM team at a time of growth and expansion. I’m looking forward to driving the firms’ branding and marketing strategy, ensuring its best-in-class offering continues to stand out in a competitive market.”

*FXCM can be compensated in several ways, which includes but are not limited to adding a mark-up to the spreads it receives from its liquidity providers, adding a mark-up to rollover, etc. Commission-based pricing is applicable to Active Trader account types.

ENDS

About FXCM:

FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards, and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one-click order execution and trading from real-time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. FXCM is a Leucadia Company.

Forex Capital Markets Limited : FCA registration number 217689 (www.fxcm.com/uk )

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

66% of retail investor accounts lose money when trading CFDs with this provider.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM EU LTD : CySEC license number 392/20 (www.fxcm.com/eu )

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

73% of retail investor accounts lose money when trading CFDs with this provider.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM Australia Pty. Limited: AFSL 309763. By trading, you could sustain a total loss of your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved. If you decide to trade products offered by FXCM AU, you must read and understand the Financial Services Guide , Product Disclosure Statement , Target Market Determination and Terms of Business on www.fxcm.com/au .

FXCM South Africa (PTY) Ltd : FSP No 46534 (www.fxcm.com/za ). Our service includes products that are traded on margin and carry a risk of losses in excess of your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved.

FXCM Markets Limited: Losses can exceed deposited funds. (www.fxcm.com/markets ).

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release

Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme

Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K

REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release

All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro

LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release

LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t

Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release

Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye